The story of Sildenafil presents a complex picture for shareholders. While the initial release generated substantial returns, the lapse of its intellectual property protection opened the floodgates to cheaper alternatives, dramatically reducing sales. This creates a particular risk for firms depending on comparable blockbuster offerings, suggesting

The legacy of Viagra, and its parent company copyright, presents a complex case study for investors. Originally a blockbuster drug, generating billions in revenue , its intellectual property lapse created a deluge of knock-off medications, significantly diminishing its dominance. While certain pharmaceutical companies may attempt to capitalize on r